NO333877B1 - Formuleringer for behandling av artritt-tilstander og anvendelse av en kombinasjon derav - Google Patents
Formuleringer for behandling av artritt-tilstander og anvendelse av en kombinasjon derav Download PDFInfo
- Publication number
- NO333877B1 NO333877B1 NO20056161A NO20056161A NO333877B1 NO 333877 B1 NO333877 B1 NO 333877B1 NO 20056161 A NO20056161 A NO 20056161A NO 20056161 A NO20056161 A NO 20056161A NO 333877 B1 NO333877 B1 NO 333877B1
- Authority
- NO
- Norway
- Prior art keywords
- extract
- saligenin
- procyanidins
- glucosamine
- salix
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 238000009472 formulation Methods 0.000 title claims abstract description 14
- 206010003246 arthritis Diseases 0.000 title abstract description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 27
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 claims description 12
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims description 12
- 229920002414 procyanidin Polymers 0.000 claims description 12
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 claims description 12
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 claims description 11
- 240000007551 Boswellia serrata Species 0.000 claims description 10
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 10
- 241000124033 Salix Species 0.000 claims description 10
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 9
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 9
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 9
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 9
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 8
- 240000006365 Vitis vinifera Species 0.000 claims description 8
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 8
- 229940097043 glucuronic acid Drugs 0.000 claims description 8
- 235000002532 grape seed extract Nutrition 0.000 claims description 8
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 claims description 7
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 claims description 7
- 241001657585 Rudra Species 0.000 claims description 7
- 229950002441 glucurolactone Drugs 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 244000052707 Camellia sinensis Species 0.000 claims description 5
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 5
- 235000006468 Thea sinensis Nutrition 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 230000002917 arthritic effect Effects 0.000 claims description 4
- 241000209507 Camellia Species 0.000 claims description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 3
- 235000018597 common camellia Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- 235000007882 dietary composition Nutrition 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- KNFZEFUDYBVCQP-VZFHVOOUSA-N (2s,3s,4s,5r)-2,3,4,5-tetrahydroxy-6,7-dioxooctanoic acid Chemical compound CC(=O)C(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O KNFZEFUDYBVCQP-VZFHVOOUSA-N 0.000 claims 3
- 241001299682 Salix purpurea Species 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 210000000845 cartilage Anatomy 0.000 abstract description 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920002770 condensed tannin Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
- 241001608538 Boswellia Species 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001697 butter ester Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 229960004590 diacerein Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Road Signs Or Road Markings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
2005-12-23 S a m m e n d r a g Foreliggende oppfinnelse vedrører formuleringer omfattende kombinasjoner av analgetikum/anti-inflammatoriske, immunmodulering og bruskgjenoppbyggende midler for behandlingen av revmatoid artritt og mer generelt av artritt-tilstander.
Description
OMRÅDE FOR OPPFINNELSEN
Foreliggende oppfinnelse vedrører formuleringer omfattende kombinasjoner av analgetikum/anti-inflammatoriske, immunmodulerende og bruskgjenoppbyggende midler for behandlingen av revmatoid artritt og mer generelt av artritt-tilstander, og den vedrører også anvendelse av en kombinasjon derav.
Kombinasjonen av disse midlene, som virker gjennom ulike virkemekanismer, reduserer smerte og forebygger progresjonen av artikulasjonsskader.
TEKNOLOGISK BAKGRUNN
Revmatoid artritt er en kronisk degenerativ lidelse som påvirker en stor andel av de eldre ved å forårsake alvorlige problemer for pasienter. Revmatoid artritts patoge-nese og artritt-tilstander gjelder først immunsystemet og deretter inflammatoriske tilstander som bryter ned de intra-artikulare overflatene forårsakende deforme-ringsskader som er irreversible og smertefulle.
Fra teknikkens stand skal også følgende dokumenter kort nevnes: CHRUSABIK S. ET AL., «Treatment of Rheumatic Pain with Herbal Medicine in Europe», Pain Di-gest, vol. 8, no. 4, 1998, s. 231-236; ZHAO J. ET AL., «Anti-tumor promoting activ-ity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3'-gallate as the most effective antioxidant constituent», Carcinogenesis, vol. 20, no. 9, 1999, s. 1737-1745; US 5629351 A; US 20020010168 Al; US 4870061 A; og EP 0864580 A2.
SAMMENFATNING AV OPPFINNELSEN
Foreliggende oppfinnelse vedrører sammensetninger omfattende en kombinasjon av aktive prinsipper i stand til å indusere spesielt effektive terapeutiske effekter uten vesentlige bivirkninger selv etter langvarige behandlinger.
De farmasøytiske formuleringene ifølge oppfinnelsen omfatter:
- ren saligenin eller derivater derav eller ekstrakter inneholdende dem valgt fra saligenin-anriket Salix rudra-ekstrakt, - vesentlig ren boswellin-syre eller et semi-syntetisk derivat derav eller et boswellin-syre-anriket Boswellia serrata- ekstrakt, - procyanidiner fra Vitis vinifera eller fra Camellia sinensis eller rhein eller lipofile derivater derav,
- N-acetyl-glukosamin,
- glukuronsyre eller glukuronolakton.
Eksempler på saligeninderivater omfatter eddik- eller smørestere, mens eksempler på boswellin-syrederivater omfatter farmasøytisk akseptable salter eller estere.
Formuleringene ifølge oppfinnelsen vedrører fortrinnsvis:
- Salix rudra-ekstrakt inneholdende 25 vekt% saligenin,
- Boswellia serrata-ekstrakt inneholdende 20 vekt% boswellin-syre,
- procyanidiner fra Vitis vinifera eller fra Camellia sinensis valgfritt kompleksert med fosfolipider eller rhein eller lipofile derivater derav,
- N-acetyl-glukosamin,
- glukuronsyre eller glukuronolakton.
Salix wdra-ekstraktet, Boswellia serrata-ekstraktet, procyanidiner, N-acetyl-glukosamin, glukuronsyre eller glukuronolakton er foretrukket til stede i formuleringene i henholdsvis 2:l:l:l:l-vektforhold.
Formuleringene vil inneholde typisk 100 til 500 mg av 25 % Sa//x-ekstrakt, 50 til 150 mg procyanidiner valgfritt i form av komplekser med fosfolipider, 20 til 200 mg Boswellia serrata- ekstrakt, 10 til 500 mg hver av glukosamin og glukuronsyre eller glukuronolakton.
Proantocyanidinene fra Vitis vinifera kan oppnås ifølge det som er beskrevet i GB-A-1541469 eller FR-A-2092743 eller i EP 348781, mens de tilsvarende fosfolipidkompleksene er kjent fra US 4.963.527, Camellia s/nens/s-ekstrakter er for eksempel beskrevet i EP 814823.
Boswellia og boswellin-syre kan fremstilles ifølge kjente fremgangsmåter og er kommersielt tilgjengelig så vel som de saligenin-anrikede Salix rudra-ekstraktene.
Formuleringene vil være i form av myke eller harde gelatinkapsler, tabletter eller andre former passende for oral administrasjon. Foretrukket er kapslene inneholdende Enothera biennis- o\) e som bærer.
Procyanidinene fra Vitis vinifera eller Camellia sinensis utøver anti-radikal påvirk-ning og inhiberer proteoglykaner-hydrolyserende metall-proteaser, de interagerer også synergistisk med cyklooksygenase 2 (COX-2) som inhiberer komponenter til stede i Salix- og flosive///a-ekstrakter.
Som et alternativ til proantocyanidiner, kan visse antrakinoner, hovedsakelig rhein eller lipofile derivater derav slik som diacerhein, anvendes, som reduserer cellepro-liferasjon og stimulerer proteoglykansynteser.
N-acetyl-glukosamin, glukuronsyre eller glukuronolakton, som kan vurderes som byggesteinene i bindevevet, kompletterer den terapeutiske profilen til formuleringene ifølge oppfinnelsen, idet de promoterer resyntesene av proteoglykaner i leddene, som er en viktig restitusjonsprosess som, sammen med de ovennevnte faktorene kan medvirke til en symptomatisk bedring.
Sammensetningene ifølge oppfinnelsen kan administreres for vedvarende bruk, i en eller repeterte daglige administrasjoner, til det oppnås bedring eller lindring av symptomene.
Foreliggende oppfinnelse vedrører også anvendelse av en kombinasjon av:
- ren saligenin eller derivater derav eller ekstrakter inneholdende dem valgt fra saligenin-anriket Salix rudra-ekstrakt, - vesentlig ren boswellin-syre eller et semi-syntetisk derivat derav eller et boswellin-syre-anriket Boswellia serrata-ekstrakt, - procyanidiner fra Vitis vinifera eller fra Camellia sinesnis eller rhein eller lipofile derivater derav,
- N-acetyl-glukosamin,
- glukuronsyre eller glukoronolakton
for fremstilling av farmasøytiske, næringslegemidler eller dietetiske sammensetninger for behandlingen av revmatoid artritt og artritt-tilstander.
Følgende eksempler illustrerer oppfinnelsen ytterligere.
Eksempel I - Fremstilling av cellulose-kapsler
Hver kapsel inneholder:
Eksempel II - Fremstilling av kapsler
Hver kapsel inneholder:
Formuleringen i eksempel I, når administrert til pasienter som lider av revmatoid artritt eller artritt-tilstander, viste konsistente kliniske resultater når det gjelder smertereduksjon, bedre mobilitet i de skadede lemmene, biopsiundersøkelse av leddende og følelse av velvære.
Claims (6)
1. Formuleringer omfattende: - ren saligenin eller derivater derav eller ekstrakter inneholdende dem valgt fra saligenin-anriket Salix rudra-ekstrakt, - vesentlig ren boswellin-syre eller et semi-syntetisk derivat derav eller et boswellin-syre-anriket Boswellia serrata-ekstrakt, - procyanidiner fra Vitis vinifera eller fra Camellia sinensis eller rhein eller lipofile derivater derav, - N-acetyl-glukosamin, - glukuronsyre eller glukoronolakton.
2. Formuleringer ifølge krav 1 omfattende: - Salix rudra-ekstrakt inneholdende 25 vekt% av saligenin, - Boswellia serrata- ekstrakt inneholdende 20 vekt% boswellin-syre, - procyanidiner fra Vitis vinifera eller fra Camellia sinensis valgfritt kompleksert med fosfoslipider eller rhein eller lipofile derivater derav, - N-acetyl-glukosamin, - glukuronsyre eller glukoronolakton.
3. Formuleringer ifølge krav 1, hvori Salix wdra-ekstraktet, Boswellia serrata-ekstraktet, procyanidiner, N-acetyl-glukosamin, glukuronsyre eller glukuronolakton er til stede i henholdsvis 2:l:l:l:l-vektforhold.
4. Formuleringer ifølge krav 2 inneholdende 100 til 500 mg av 25 % Salix rubra-ekstrakt, 50 til 150 mg procyanidiner eventuelt i form av komplekser med fosfolipider, 20 til 200 mg Boswellia serrata- ekstrakt og 10 til 500 mg hver av glukosamin, glukuronsyre eller glukuronolakton.
5. Formuleringer ifølge et hvilket som helst av kravene 1-3 i form av kapsler inneholdende Enothera biennis- o\ je som bærer.
6. Anvendelse av en kombinasjon av: - ren saligenin eller derivater derav eller ekstrakter inneholdende dem valgt fra saligenin-anriket Salix rudra-ekstrakt, - vesentlig ren boswellin-syre eller et semi-syntetisk derivat derav eller et boswellin-syre-anriket Boswellia serrata- ekstrakt, - procyanidiner fra Vitis vinifera eller fra Camellia sinesnis eller rhein eller lipofile derivater derav, - N-acetyl-glukosamin, - glukuronsyre eller glukoronolakton
for fremstilling av farmasøytiske, næringslegemidler eller dietetiske sammensetninger for behandlingen av revmatoid artritt og artritt-tilstander.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001311A ITMI20031311A1 (it) | 2003-06-27 | 2003-06-27 | Formulazioni per il trattamento di disturbi artrosici. |
| PCT/EP2004/005875 WO2005002611A1 (en) | 2003-06-27 | 2004-06-01 | Formulations for the treatment of arhritis conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20056161L NO20056161L (no) | 2005-12-23 |
| NO333877B1 true NO333877B1 (no) | 2013-10-07 |
Family
ID=30131307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20056161A NO333877B1 (no) | 2003-06-27 | 2005-12-23 | Formuleringer for behandling av artritt-tilstander og anvendelse av en kombinasjon derav |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8343554B2 (no) |
| EP (1) | EP1648484B1 (no) |
| JP (1) | JP2007513051A (no) |
| KR (2) | KR20110039400A (no) |
| CN (1) | CN1812802A (no) |
| AT (1) | ATE414526T1 (no) |
| AU (1) | AU2004253242B2 (no) |
| BR (1) | BRPI0411895B1 (no) |
| CA (1) | CA2530494C (no) |
| DE (1) | DE602004017871D1 (no) |
| DK (1) | DK1648484T3 (no) |
| ES (1) | ES2315662T3 (no) |
| IL (1) | IL172773A (no) |
| IT (1) | ITMI20031311A1 (no) |
| NO (1) | NO333877B1 (no) |
| NZ (1) | NZ544400A (no) |
| PL (1) | PL1648484T3 (no) |
| PT (1) | PT1648484E (no) |
| RU (1) | RU2349336C2 (no) |
| SI (1) | SI1648484T1 (no) |
| WO (1) | WO2005002611A1 (no) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20040439A1 (it) * | 2004-09-16 | 2004-12-16 | Ca Di Group S R L | Prodotto con azione antinfiammatoria selettiva e azione contro la fibrogenesi tissutale. |
| ITMI20051349A1 (it) * | 2005-07-14 | 2007-01-15 | Indena Spa | Estratto di salice uso e formulazioni che lo contengono |
| CN100417415C (zh) * | 2006-06-28 | 2008-09-10 | 文彦春 | 浸润治疗关节炎的药物 |
| EP1886712A1 (en) | 2006-08-08 | 2008-02-13 | Indena S.P.A. | Compositions for the treatment of chronic degenerative inflammatory conditions |
| FR2907339B1 (fr) * | 2006-10-20 | 2009-04-24 | Inneov Lab | Composition comprenant de la glucosamine et au moins un polyphenol. |
| CN101371823B (zh) * | 2007-03-19 | 2010-09-15 | 上海慈瑞医药科技有限公司 | 二乙酰大黄酸缓释胶囊的制备工艺 |
| FR2918376B1 (fr) | 2007-07-04 | 2011-10-28 | Mathieu Borge | Compositions liquides ou pateuses destinees a l'apport en elements essentiels a la synthese et a la constitution des proteoglycanes, notamment pour le traitement de la degradation du cartilage |
| JP2010538058A (ja) * | 2007-09-04 | 2010-12-09 | カトリック ユニバーシティ インダストリー アカデミック コーオペレイション ファウンデーション | ビティス・ビニフェラの種抽出物の調製方法及び該抽出物を含む関節リウマチの予防または治療用の医薬組成物 |
| WO2010029578A2 (en) | 2008-09-15 | 2010-03-18 | Ganga Raju Gokaraju | Synergistic anti-inflammatory compositions comprising boswellia serrata extracts |
| KR101096574B1 (ko) * | 2008-12-12 | 2011-12-20 | 에이치 엘 지노믹스(주) | 유럽종 포도의 씨 추출물을 함유하는 골다공증 예방 또는 치료용 약학 조성물 |
| KR101099021B1 (ko) * | 2009-04-24 | 2011-12-28 | 에이치 엘 지노믹스(주) | 유럽종 포도의 씨 추출물을 함유하는 골관절염 예방 또는 치료용 약학 조성물 |
| JP5734578B2 (ja) * | 2009-09-03 | 2015-06-17 | ナガセケムテックス株式会社 | ヒアルロン酸増量剤 |
| WO2011079203A1 (en) * | 2009-12-23 | 2011-06-30 | Bae Systems Aerospace & Defense Group Inc. | Quick release buckle with dual release |
| CN102711781B (zh) | 2010-02-15 | 2016-05-04 | 莱拉营养食品有限公司 | 一种乳香低极性树胶脂提取物及其协同增效的组合物 |
| US8828377B2 (en) | 2010-03-15 | 2014-09-09 | Laila Nutraceuticals | Boswellia oil, its fractions and compositions for enhancing brain function |
| WO2012177825A1 (en) | 2011-06-21 | 2012-12-27 | Bvw Holding Ag | Medical device comprising boswellic acid |
| RU2476213C1 (ru) * | 2012-02-15 | 2013-02-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия имени Н.Н. Бурденко Министерства здравоохранения и социального развития" (ГБОУ ВПО ВГМА им. Н.Н. Бурденко Минздравсоцразвития России) | Способ комплексного лечения вторичного остеоартроза при ревматоидном артрите |
| JP6270362B2 (ja) * | 2013-07-17 | 2018-01-31 | 日本水産株式会社 | 関節痛改善剤 |
| JP6153436B2 (ja) * | 2013-09-27 | 2017-06-28 | 小林製薬株式会社 | 経口組成物 |
| US9975917B1 (en) | 2017-09-20 | 2018-05-22 | King Saud University | Pentacyclic triterpenoidal derivatives |
| CN111110863A (zh) * | 2020-01-21 | 2020-05-08 | 郑州大学 | 大黄酸磷脂复合物及其制备方法和应用、大黄酸磷脂复合物长循环脂质体及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3970M (no) | 1963-11-26 | 1966-02-28 | ||
| GB1155973A (en) * | 1965-06-26 | 1969-06-25 | Ajinomoto Kk | Spiroacetal Diamine Derivatives and their use as Curing Agents for Epoxy Resins |
| DE3347522A1 (de) * | 1983-12-30 | 1985-07-11 | Troponwerke GmbH & Co KG, 5000 Köln | N-glycosylierte carbonsaeureamid-derivate als mittel bei der bekaempfung von erkrankungen des rheumatischen formenkreises |
| DE3602670A1 (de) | 1986-01-29 | 1987-07-30 | Speck Ulrich | Verwendung von n-acetylglucosamin zur therapie degenerativer gelenkprozesse und verwandter erkrankungen |
| US5629351A (en) | 1995-04-13 | 1997-05-13 | Council Of Scientific & Industrial Research | Boswellic acid compositions and preparation thereof |
| DE19531067A1 (de) | 1995-08-23 | 1997-02-27 | Hermann P T Prof Dr Med Ammon | Verwendung von Boswelliasäure und ihren Derivaten zur Hemmung der normalen und gesteigerten Leukozytenelastase- oder Plasminaktivität |
| US5762936A (en) * | 1996-09-04 | 1998-06-09 | Biotics Research Corporation | Antioxidant derived from lentil and its preparation and uses |
| JP4153057B2 (ja) | 1997-03-10 | 2008-09-17 | 中国化薬株式会社 | Ｄ−グルクロノラクトンの製造方法 |
| US6107334A (en) * | 1998-02-23 | 2000-08-22 | Wake Forest University | Dietary control of arachidonic acid metabolism |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| EP1202620A1 (en) * | 1999-05-14 | 2002-05-08 | The Regents of the University of California | Anti-inflammatory therapy for inflammatory mediated infection |
| JP2002153294A (ja) * | 2000-11-21 | 2002-05-28 | Hayashibara Biochem Lab Inc | グルクロン酸類及び／又はｄ−グルクロノラクトンの製造方法とその用途 |
| US6451045B1 (en) * | 2001-02-22 | 2002-09-17 | Alsius Corporation | Heat exchange catheter having a helically wrapped heat exchanger |
| US6541045B1 (en) * | 2002-01-04 | 2003-04-01 | Nutraceutical Corporation | Herbal composition and method for combating inflammation |
-
2003
- 2003-06-27 IT IT001311A patent/ITMI20031311A1/it unknown
-
2004
- 2004-01-06 US US10/562,205 patent/US8343554B2/en not_active Expired - Fee Related
- 2004-06-01 KR KR1020117007487A patent/KR20110039400A/ko not_active Application Discontinuation
- 2004-06-01 WO PCT/EP2004/005875 patent/WO2005002611A1/en active Application Filing
- 2004-06-01 NZ NZ544400A patent/NZ544400A/en unknown
- 2004-06-01 DE DE602004017871T patent/DE602004017871D1/de not_active Expired - Lifetime
- 2004-06-01 BR BRPI0411895A patent/BRPI0411895B1/pt not_active IP Right Cessation
- 2004-06-01 CN CNA2004800177557A patent/CN1812802A/zh active Pending
- 2004-06-01 EP EP04735566A patent/EP1648484B1/en not_active Expired - Lifetime
- 2004-06-01 KR KR1020057024594A patent/KR101119418B1/ko active IP Right Grant
- 2004-06-01 DK DK04735566T patent/DK1648484T3/da active
- 2004-06-01 ES ES04735566T patent/ES2315662T3/es not_active Expired - Lifetime
- 2004-06-01 JP JP2006515812A patent/JP2007513051A/ja active Pending
- 2004-06-01 AU AU2004253242A patent/AU2004253242B2/en not_active Ceased
- 2004-06-01 PT PT04735566T patent/PT1648484E/pt unknown
- 2004-06-01 RU RU2005140573/15A patent/RU2349336C2/ru not_active IP Right Cessation
- 2004-06-01 AT AT04735566T patent/ATE414526T1/de active
- 2004-06-01 CA CA2530494A patent/CA2530494C/en not_active Expired - Fee Related
- 2004-06-01 PL PL04735566T patent/PL1648484T3/pl unknown
- 2004-06-01 SI SI200430968T patent/SI1648484T1/sl unknown
-
2005
- 2005-12-22 IL IL172773A patent/IL172773A/en active IP Right Grant
- 2005-12-23 NO NO20056161A patent/NO333877B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SI1648484T1 (sl) | 2009-02-28 |
| RU2005140573A (ru) | 2006-06-10 |
| PL1648484T3 (pl) | 2009-04-30 |
| IL172773A (en) | 2010-12-30 |
| BRPI0411895A (pt) | 2006-08-29 |
| EP1648484A1 (en) | 2006-04-26 |
| KR20110039400A (ko) | 2011-04-15 |
| CA2530494C (en) | 2013-04-30 |
| ITMI20031311A0 (it) | 2003-06-27 |
| ATE414526T1 (de) | 2008-12-15 |
| KR20060032147A (ko) | 2006-04-14 |
| RU2349336C2 (ru) | 2009-03-20 |
| ITMI20031311A1 (it) | 2004-12-28 |
| NO20056161L (no) | 2005-12-23 |
| BRPI0411895B1 (pt) | 2015-11-10 |
| AU2004253242B2 (en) | 2010-02-18 |
| EP1648484B1 (en) | 2008-11-19 |
| CN1812802A (zh) | 2006-08-02 |
| WO2005002611A1 (en) | 2005-01-13 |
| DE602004017871D1 (de) | 2009-01-02 |
| JP2007513051A (ja) | 2007-05-24 |
| US8343554B2 (en) | 2013-01-01 |
| PT1648484E (pt) | 2009-01-09 |
| ES2315662T3 (es) | 2009-04-01 |
| AU2004253242A1 (en) | 2005-01-13 |
| CA2530494A1 (en) | 2005-01-13 |
| US20060280811A1 (en) | 2006-12-14 |
| DK1648484T3 (da) | 2009-01-19 |
| NZ544400A (en) | 2009-04-30 |
| IL172773A0 (en) | 2006-04-10 |
| KR101119418B1 (ko) | 2012-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO333877B1 (no) | Formuleringer for behandling av artritt-tilstander og anvendelse av en kombinasjon derav | |
| Perrinjaquet‐Moccetti et al. | Food supplementation with an olive (Olea europaea L.) leaf extract reduces blood pressure in borderline hypertensive monozygotic twins | |
| ES2261632T3 (es) | Composiciones que comprenden proteoglicano y su uso para tratamiento de afecciones inflamatorias. | |
| WO2009137510A2 (en) | Method for protecting humans against superficial vasodilator flush syndrome | |
| Zorniak et al. | Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences | |
| AU2007283122B2 (en) | Compositions for the treatment of chronic degenerative inflammatory conditions | |
| EP3773525A1 (en) | Composition for the treatment of inflammatory diseases | |
| JP2002516829A (ja) | 結合組織の保護、治療及び修復のための作用物質及び方法。 | |
| ES2289806T3 (es) | Reduccion de la concentracion de homocisteina serica usando allium y vitaminas. | |
| US20040043087A1 (en) | Proteoglycan compositions for the treatment of cardiovascular inflammatory diseases | |
| JP2011195534A (ja) | ヒアルロン酸産生促進剤、抗老化剤およびしわ改善剤 | |
| Phuong et al. | Effects of Hamo nk hard capsule on serum lipid profiles in dyslipidemia experimental animals | |
| Pizzorno Jr | Natural medicine approach to treating osteoarthritis | |
| ITRM960279A1 (it) | Uso di integratore dietetico comprendente chitosano, idrossicitrato di garcinia, cambogia e cromo organico nel trattamento della dislipi= | |
| US20040247709A1 (en) | Composition and method for treating upper abdominal pain and cramping | |
| US20200281877A1 (en) | Method for prevention and treatment of acne, eczema, psoriasis, and related dermatological conditions with composition comprising a sphingolipid and sulphur compounds | |
| JP2020528462A (ja) | 片頭痛の予防及び治療に使用するための栄養補助食品 | |
| ITMI20082285A1 (it) | Composizioni per la prevenzione e il trattamento dell osteo-artrite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |